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ABSTRACT
The human JC polyomavirus (JCPyV) persists as an asymptomatic infection in the
kidneys of healthy individuals within the majority of the global population. Viral
infection of JCPyV is established through peroral transmission due to poor sanitary
practices. In severely immunocompromised individuals, JCPyV migrates to the central
nervous system (CNS), resulting in the fatal and incurable demyelinating disease
progressive multifocal leukoencephalopathy (PML). Virus-host cell interactions regulate
infectious processes and influence viral pathogenesis. JCPyV attachment to host cells is
mediated by α2,6-linked LSTc while internalization is mediated by 5-hydroxytryptamine
serotonin type 2 receptors (5-HT2Rs). Activation of 5-HT2Rs can induce intracellular
calcium (Ca2+) release upon ligand binding to activate the inositol triphosphate receptor
(IP3R) signaling pathways. The goal of this project was to determine the role of
intracellular Ca2+ flux in JCPyV infection. JCPyV induces Ca2+ flux from the ER almost
immediately upon infection. Limiting Ca2+ release from the ER by inhibition of the IP3R
with chemical antagonists significantly reduced JCPyV infection in both human kidney
and brain cells, demonstrating a dependence on Ca2+ flux to regulate JCPyV infection.
Although, JCPyV-induced Ca2+ flux occurs at times consistent with viral attachment and
entry, analyses of these steps by flow cytometric assays, revealed that JCPyV attachment
and entry were not affected by modulation of Ca2+ flux. These findings demonstrate that
Ca2+ flux is regulated upon JCPyV infection and provide important insights into the
activation of signaling pathways to drive the infectious process. In the future, this work
can increase our understanding of PML pathogenesis and aid in the development of novel
PML therapeutics.
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INTRODUCTION

Overview
Defined as obligate intracellular parasites, viruses are comprised of either an RNA
or DNA genome, which is surrounded by a capsid composed of viral proteins, and
sometimes a lipid envelope which encases the capsid1. For a virus to replicate, it must
invade a host cell that is both susceptible and permissive to infection, as viruses usurp
host cell machinery to mediate their replication and cause disease2. As a result, the host
immune system develops specialized mechanisms to identify and destroy invading
pathogens. A body’s first line of defense against invading pathogens are physical barriers
such as epithelial tissues, stomach acid, and saliva3. To combat these defenses, pathogens
have evolved to interact with cellular receptors and trick the host into internalizing them.
Once inside, however, the pathogen must inhibit the activation of host intrinsic, innate,

Figure 1. Schematic of JCPyV genome: early and late genes. The non-coding
control region (NCCR) contains the open reading frame (ORF) for the early genes
(counter clockwise) and late genes (clockwise). The early genes include large T
antigen (TAg) while the late gene include structural proteins such as viral protein
1 (VP1). Used with permission from Ferenczy et al. 2012. Clinical Microbiology
Reviews. 25, 471–506.
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and adaptive immune responses to avoid destruction1. Due to the efficiency of the host
immune system, some viruses are only capable of inducing disease once the immune
system has been suppressed and are therefore defined as opportunistic viruses1.
In 1971, a novel opportunistic virus was isolated from a patient suffering from
progressive multifocal leukoencephalopathy (PML) and was named the human JC
polyomavirus (JCPyV) after the patient’s initials4. The human JCPyV is non-enveloped
with a capsid comprised of three viral proteins (VP1, VP2, VP3) and is ~45 nm in
diameter5. The genome is circularized double stranded DNA containing one set of early
and late-transcribed genes with a total length of 5130 base pairs (Figure 1)6. However,
while the physical properties of JCPyV have been well examined, the infectious lifecycle
of the virus remains poorly understood.
JCPyV is thought to be transmitted via peroral transmission during early
childhood due to poor sanitation practices, as it is shed in the urine and can be found in
untreated wastewater7,8. Data based on recent serological studies suggest that at least 5080% of the human population is infected with JCPyV9. In healthy individuals, JCPyV
establishes itself as an asymptomatic infection in the kidney and remains there as a
lifelong, persistent infection controlled by the patient’s immune system8. When an
individual becomes severely immunocompromised due to HIV infection, or through the
use of immunosuppressive therapies for immune-mediated diseases like multiple
sclerosis (MS), JCPyV can migrate from the kidney to the central nervous system
(CNS)10. Within the CNS, JCPyV can infect the glial cells, astrocytes and
oligodendrocytes, and result in their lytic destruction. These cells are critical for the
production and maintenance of myelin within the brain and are necessary for healthy
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brain function5. The destruction of the myelin-producing cells leads to severe
demyelination, resulting in a disease called progressive multifocal leukoencephalopathy
(PML)11.
Due to gaps in our knowledge concerning viral-host cell interactions there are no
effective therapies or treatments for either JCPyV infection or PML. As a result, the
disease proves fatal to the majority of patients within 1 year of symptom onset4. To
develop successful treatments, it is imperative to first understand the viral-host cell
interactions that allows the virus to evade the immune system, persist within the host, and
eventually become the etiological agent for PML. Further research investigating the
signaling pathways that regulate these viral-host cell interactions in JCPyV infection will
provide necessary insights into the infectious lifecycle and could serve as a platform for
the development of effective treatments for populations at risk for PML.
Progressive multifocal leukoencephalopathy
While JCPyV was originally isolated in 1971, the first descriptions of PML were
noted as early as 1930, and officially defined as a novel disease in 19584,14. The fatal
disease was identified due to the destruction of the oligodendrocytes along with
morphological changes in astrocytes and oligodendrocytes4. PML has an incidence rate
(5-10%) in AIDS patients and is described as an AIDS defining illness15. Due to the
increased use of immunosuppressive therapies for immune-mediated diseases like MS
and Crohn’s disease, the incidence of PML has increased in these populations15.
However, due to a lack of effective treatments for JCPyV infection or PML, the best
options for patients are to treat the underlying immunosuppression by administering
highly active antiretroviral therapy (HAART) for those infected with HIV or cease
3

Figure 2. Images of PML lesions and rapid disease progression. Magnetic
resonance imaging scans utilizing 3D Flair techniques. White matter located in
the brain marks the development of plaques over 2-months. Red arrow points to
areas of PML lesions. Image credit: Biogen Idec.

immunomodulatory therapies for the preexisting disease like MS16. As a result, therapies
are ranked in classes based upon their likelihood to increase a patient’s risk of developing
PML4. The risk stratification is calculated based upon the risks and benefits to the patient
by taking the therapy and ensures that patients who are at a high risk of developing this
fatal disease are routinely examined4.
Diagnosis of PML is accomplished through multiple methods. One common
methodology is magnetic resonance imaging (MRI) to examine the brain for the loss of
myelin, which appears as white plaque regions in the brain or CNS (Figure 2)7. In
addition to identification of plaques through MRI, the preliminary diagnosis must also be
confirmed through the presence of biomarkers, assays determining JCPyV load, and
assays for JCPyV mRNA. A strong biomarker for PML in MS patients receiving the drug
Natalizumab is CD62L, a selectin present on CD4+ T cells, that has been shown to be
expressed at lower levels in patients that develop PML7. Patients can also be tested for
the presence of JCPyV antibodies and genetic material in urine samples through PCR
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techniques 7. Early detection of JCPyV infection for patients at risk of developing AIDS
or beginning immunosuppressive therapies alerts physicians to closely monitor those
patients for the development of PML.
Upon disease onset, PML can develop in multiple regions of the brain and often
spreads to multiple areas17. As a result, there is a wide range of symptoms that may be
presented based on which region of the brain is being affected15. Classic symptoms can
include vision impairment, loss of memory, and hemiparalysis15. It is also common for
the afflicted individual to experience personality disorders upon symptom onset8. Once a
patient begins showing clinical symptoms, PML proves fatal to the majority of patients
within one year4. With no effective therapies or treatments available for either this
disease or JCPyV infection, the only option patients receiving immunosuppressive
therapies have is to cease immunosuppressive therapies. In doing so, however, patients
face the progression of the underlying condition such as cancer, MS, or Crohn’s
disease6,8,19. Additionally, ending immunosuppressive therapies also increases the
patient’s risk of developing immune reconstruction inflammatory syndrome (IRIS)18.
IRIS is caused by a rapid return of immune cells within the CNS and results in severe
inflammatory responses and worsen the underlying disease condition18. Conversely, for
individuals with HIV or AIDS initiation of HAART can delay onset of PML19.
JCPyV infectious lifecycle
Before JCPyV can disseminate through its host and cause PML, it must
successfully establish a persistent infection. A successful JCPyV infection is dependent
upon the virus encountering a permissive host cell, requiring the cell to have specific
functionalities that support viral infection. Research has found that JCPyV initially
5

attaches to host cells via α2,6 linked sialic acids on lactoseries tetrasaccharide c (LSTc)12.
This virus-host cell interaction is mediated by the JCPyV capsid protein, viral protein 1
(VP1), which contains multiple binding sites for LSTc12. Interestingly, research suggests
that in patients diagnosed with PML, VP1 has undergone mutations indicating that these
mutations may be required for JCPyV spread from initial sites of infection to the CNS21.
Following attachment to LSTc, JCPyV requires serotonin receptors to aid in viral
infection23.
Serotonin 5-hydroxytryptamine (5-HT) receptors are seven transmembrane
spanning G-protein-coupled receptors22. While there are multiple families of 5-HTRs,
only the subtype 5-HT2Rs have been shown to be essential for JCPyV infection22,23.
Currently, the mechanism by which 5-HT2Rs mediate JCPyV internalization is poorly
understood. However, inhibition of the 5-HT2Rs inhibits JCPyV infection but has no
effect on viral attachment to host cells 23,24. Interestingly, when 5-HT2Rs are expressed in
human kidney cells, which naturally do not express the receptors but do express LSTc,
the cells gain the ability to internalize JCPyV and can become infected22. Recent work
from the Maginnis Laboratory suggests that JCPyV-mediated activation of 5-HT2Rs
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results in viral
internalization via
clathrin-mediated
endocytosis
(Mayberry and
Maginnis,
unpublished data).
This data
Figure 3. JCPyV internalization and infectivity pathway. JCPyV attaches to α2,6 LSTc
receptor and enters cells by 5-hydroxytryptamine receptors (5-HT2)R through clathrin-mediated
endocytosis. JCPyV traffics to early endosomes and cav-1 positive late endosomes, then to the
ER where it undergoes uncoating, and enters the nucleus where transcription and replication
occur. Used with permission from Maginnis et al. 2015. J. Neurovirol. 21, 601–13.

corroborates the
finding, which

showed that inhibition of clathrin-mediated endocytosis reduced JCPyV internalization25.
Once inside the cell, JCPyV traffics through the cytoplasm via endosomes and caveolin-1
vesicles5. The virus is then deposited into the endoplasmic reticulum (ER) where the
capsid undergoes a partial uncoating event prior to translocation to the nucleus for viral
transcription and replication (Figure 3)26.
Upon arrival in the nucleus, the JCPyV genome is transcribed in a temporallyregulated fashion in which the early genes are transcribed first (Figure 1)4. One of the
early genes codes for the protein large tumor antigen (large T antigen (T Ag)), which is a
major regulator of JCPyV replication4. Accumulation of T Ag within the cells promotes
the transition from the production of early gene products, to late gene products, including
VP16. Additionally, T Ag is capable of binding to host cell DNA to promote its transition
from the G0 to S phase through the activation of host transcription factors4. While not all
transcription factors required for JCPyV transcription have not been identified, some
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have been characterized that play an important role in JCPyV transcription including
nuclear factor of activated T cells (NFAT)28.
NFAT is regulated by the serine/threonine phosphatase calcineurin, which is
activated by calcium (Ca2+) flux from the ER through the interaction of inositol
triphosphate (IP3) with its receptor (IP3R)29. Upon activation, NFAT migrates from the
cytoplasm to the nucleus and directly binds to promoter regions on the JCPyV genome to
initiate transcription28. Inhibition of calcineurin utilizing the chemical inhibitor
Cyclosporine a (CsA), results in a significant reduction in JCPyV infection28. Manley et
al. demonstrated the importance of NFAT binding to JCPyV DNA to promote
transcription of both the early and late viral genes. While these findings suggest the
importance of NFAT regulation in JCPyV infection, the role of the IP3R signaling
cascade in NFAT activation during JCPyV infection remains uncharacterized.

Figure 4. 5-HT2R-activation of Ca2+/CaM signaling pathway. Activation of 5-HT2R leads to
IP3 activation of the IP3R causing a release of Ca2+ from the ER, leading to the activation of
calmodulin (CaM), which then binds to specific sites on the intracellular loops on the 5-HT2R,
and/or calcineurin, which activates nuclear factor of activated T cells (NFAT), a transcription
factor required for JCPyV infection. Inhibition of IP3R was accomplished utilizing the
competitive inhibitor, 2-APB.
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IP3R-mediated calcium signaling
While the role of 5-HT2Rs in JCPyV entry and infection are not completely understood, it
is known that ligand activation of 5-HT2Rs can activate multiple signaling cascades,
which have been observed to regulate the JCPyV lifecycle20. The 5-HT2R recruits
calmodulin (CaM), which activates phospholipase C (PLC) and hydrolyses PIP2 into IP3
and diacylglycerol (DAG)29. Free IP3 binds to its receptor (IP3R) which is imbedded
within the ER membrane and elicits a flux of calcium ions (Ca2+) into the cytoplasm.
Increased cytoplasmic Ca2+ then becomes a universal regulator for a multitude of
signaling cascades within a cell including activation of calcineurin, a seine/threonine
phosphatase that regulate the activation of host transcription factors like NFAT and
cellular proliferation (Figure 4)45. Additionally, the free Ca2+ may bind to CaM and result
in binding to intracellular binding domains on the 5-HT2R, which stabilizes its expression
on the exterior of the cell.
Recent studies suggest that viruses have evolved to elicit the release of ER Ca2+
stores to drive various stages in their reproductive lifecycles. For example, the human
immunodeficiency virus (HIV) is an enveloped, negative-stranded RNA virus that
utilizes IP3R-mediated Ca2+ flux to localize Gag, viral structural proteins responsible for
virion maturation, to the plasma membrane30. At the membrane, Gag mediates viral
egress via endocytic sorting complex required for transport (ESCRT)31. Meanwhile,
Dengue virus (DENV), an enveloped, positive-stranded RNA virus, induces Ca2+ flux
from the ER to initiate store-operated Ca2+ entry (SOCE) to drive viral replication32.
Furthermore, coxsackievirus B (CVB) is a nonenveloped, positive-sense RNA virus that
utilizes IP3R-mediated Ca2+ flux to induce vacuolization of cells, which mediates viral
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internalization and trafficking through the cell33. While these viruses have different
physical structures, genomes, and egress strategies, they are all unified in their
dependence on intracellular Ca2+ to drive infection. Based on the viral-induced Ca2+ flux
pathways elicited by a wide-range of viruses and JCPyV activation of potential Ca2+driven signaling pathways through 5-HT2Rs22, MAPK26, and NFAT28, it is hypothesized
that JCPyV also depends on IP3R-mediated Ca2+ release to drive the infectious viral
lifecycle.
Research goals
The goal of this thesis research was to define the role of IP3R-mediated
intracellular Ca2+ flux from the ER in regulating JCPyV infection. Studies using an ERspecific Ca2+ reporter assay to track Ca2+ levels within the ER, suggest that JCPyV
infection induces the release of ER Ca2+ stores at 2 h post infection. To determine
whether Ca2+ flux is necessary for JCPyV infection, an IP3R chemical inhibitor was
utilized and resulted in a dose-dependent-decrease in both viral VP1 and T Ag
expression. JCPyV-induced Ca2+ flux within 0-3 h following viral infection, times that
are consistent with viral attachment and entry. To elucidate the step in the virus lifecycle
affected by the inhibition of Ca2+ flux, JCPyV attachment and internalization were
examined. However, data revealed that treatment with the IP3R inhibitor had no effect on
viral attachment or entry when compared to untreated cells. Together, these results
suggest that JCPyV activates Ca2+ flux upon infection, and Ca2+ flux regulates JCPyV
infection at a post-entry step in the virus lifecycle.
These data provide researchers with greater insight into the JCPyV infectious
lifecycle and helps to increase our general understanding of the viral-host cell interactions
10

that impact human disease. Additionally, these experiments increase our understanding of
the importance of Ca2+ signaling in viral infections within the field of virology. It is
possible that this information may provide the insights necessary to identify novel targets
for antivirals therapies for populations at risk of developing the fatal disease PML.
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MATERIALS AND METHODS

Cell culture maintenance
Cell culture experiments were conducted utilizing Lab Gard II laminar flow hoods to
maintain a sterile environment. SVG-A (human fetal glial cells transformed with SV40 T
antigen) and human embryonic kidney cell lines that stably express 5-HT2AR
(HEK293A-5-HT2AR) were generously provided from Dr. Walter Atwood’s laboratory
(Brown University). Cells were maintained in T75 flasks and were grown in a humidified
incubator at 37oC with 5% CO2. Cell lines were passaged upon visually reaching 90%
confluency, as observed using a light microscope. SVG-A cells were cultured in
Minimum Essential Medium (MEM) with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin (P/S) (Mediatech, Inc.), and 0.2% plasmocin (Invivogen).
HEK293A-5-HT2AR cells were cultured with Dulbecco’s Modified Eagle Medium
(DMEM) with the same concentrations of FBS, P/S, and plasmocin. For subculturing,
cells were detached from flasks with 4 mL of 0.5% trypsin-EDTA (Gibco, Thermo
Fischer Scientific) and incubated at 37oC for 5 mins. Following incubation, 9 mL of fresh
media was added and transferred to a 15 mL conical tube. The cell suspension was
centrifuged at 2,000 rpm for 5 min. Media was aspirated off the pelleted cells, which
were then resuspended in 10 mL of fresh complete media and divided into a new flask for
continued growth. The new T75 was incubated in a humidified incubator at 37oC and 5%
CO2 until confluency was reached again.
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Inhibition of Calcium Flux
2-APB Treatment of SVG-A cells: Wells of a 24-well plate (Grenier Bio-One) were
seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified incubator
at 37oC overnight (O/N). Once cells reached ~80% confluency by visual inspection,
media was removed, and the 2-APB (Sigma-Aldrich) inhibitor, a competitive inhibitor of
the IP3R, was added in complete MEM with a final volume of 1 mL/well (concentrations
specified in Figure Legends). Cells were then incubated at 37oC for 2 h and then infected
(described below).
2-APB Treatment of HEK293A-5-HT2AR cells: Wells of a 24-well plate (Grenier BioOne) were seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified
incubator at 37oC O/N. Once cells reached ~80% confluency by visual inspection, media
was removed, and the 2-APB inhibitor, a competitive inhibitor of the IP3R, was added in
complete MEM with a final volume of 1 mL/well (concentrations specified in Figure
Legends).
Xestospongin C treatment of SVG-A cells: Wells of a 24-well plate (Grenier Bio-One)
were seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified
incubator at 37oC O/N. Once cells reached ~80% confluency by visual inspection, media
was removed, and the Xestospongin C inhibitor, an inhibitor of the IP3R, was added in
complete MEM with a final volume of 1 mL/well (concentrations specified in Figure
Legends). Cells were then incubated at 37oC for 30 min and then infected (described
below).
U73122 Treatment of SVG-A cells: Wells of a 24-well plate (Grenier Bio-One) were
seeded with 2.4e5 cells/well in complete MEM and incubated in a humidified incubator
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at 37oC O/N. Once cells reached ~80% confluency by visual inspection, media was
removed, and the inhibitor U73122, which targets PLC, was added in complete MEM
with a final volume of 1 mL/well (concentrations specified in Figure Legends). Cells
were then incubated at 37oC for 24 h and then infected (described below).
Cellular Proliferation Assay (MTS)
To determine cytotoxic effects of chemical inhibitors, wells in a 96-well plate (Grenier
Bio-One) were seeded with 1e4 cells/well in complete MEM and incubated at 37oC O/N.
Once cells reached 80% confluency they were treated with the selected chemical, after
which fresh media was added to a final volume of 100 µL per well. A volume of 20 µL of
the MTS/PMS solution was then added, and cells were incubated at 37oC for 1 h. Post
incubation, absorbance was recorded at 490 nm utilizing a BioTek Synergy2 plate reader.
The average absorbances were calculated and compared to untreated cells at selected
timepoints.
JCPyV infection
Cells that were pretreated with a chemical, control, or transfected with ER-GCaMP had
media removed prior to infection. Cells were inoculated with JCPyV in fresh media
(multiplicity of infections (MOIs) specified in Figure Legends). Viral infections were
conducted in either complete MEM for chemical inhibitors, or phenol red-free complete
MEM for ER-GCaMP transfected cells as specified. Cells were incubated with viral
inoculums of 200 µL for 24-well plate and 40µL for a 96-well plate for 1 h incubation at
37oC, then cells were fed with 1 mL of complete MEM for a 24-well plate (Grenier BioOne), or 60 µL for a 96-well plate (Grenier Bio-One). Cells that were being examined for

14

T Ag expression were incubated for 48 hpi while those being examined for VP1
incubated for 72 hpi.
Fluorescence Focus Assay (FFA)
Following infection, cells were washed with 1 mL of 1XPBS then fixed in ice cold
methanol. Fixed cells were then incubated at -20oC for at least 10 mins, washed three
times for 10 mins with 1XPBS, and then permeabilized with PBS-0.5% TX100 during a
15-min incubation.
T Ag Staining: Following permeabilization, cells were blocked with 10% goat serum in
1XPBS at RT for 45 min. Cells were then stained for presence of T Ag utilizing the
primary PAB692 (1:50) and incubated at 37oC for 1 h (generously provided by the
Tevethia lab, Penn State). Cells were washed with 1XPBS Tween (0.01%) three times at
RT for 5 min. An anti-mouse Alexa Fluor-594 secondary antibody was used to detect the
primary antibody, and cells were incubated at 37oC for 1 h. Finally, cells were washed
with 1XPBS three times at RT for 5 min, then stored in 1XPBS Tween (0.01%) at 4oC
prior to visualization and quantitation.
VP1 Staining: Following permeabilization, cells were blocked with 10% goat serum at
RT for 45 min. Cells were stained with a primary antibody PAB597 (1:10), a hybridoma
supernatant, which produces a monoclonal antibody for JCPyV VP1 (provided by Ed
Harlow), and incubated at 37oC for 1 h. Cells were washed with 1XPBS three times at RT
for 5 min. An anti-mouse Alexa Fluor-488 secondary antibody (1:1000) (Thermo Fisher
Scientific) was used to detect the primary antibody and incubated at 37oC for 1 h. Finally,
cells were washed with 1XPBS three times at RT for 5 min and then stored in 1XPBS
Tween (0.01%) at 4oC prior to visualization and quantitation.
15

Quantification: Cells were quantified for infectivity via epifluorescence microscopy by
counting VP1+ cells in at least 5 visual fields per well in triplicate wells for 3 separate
experiments. Expression of VP1 was observed under a 10x objective for a 24-well plate
or 20x for a 96-well plate using a Nikon Eclipse Ti epifluorescence microscope. The total
number of cells/visual field was quantified by staining cellular DNA with DAPI. DAPI
positive cells were quantified using a binary created in the Nikon NIS-Elements Basic
Research software (Version 4.5), which controls for equal diameter and circularity of
DAPI+ nuclei based upon threshold fluorescence. The percentage of infected cells was
calculated by dividing VP1+ cells by the total number of cells, and then normalizing
values to the negative control (i.e. DMSO).
Flow cytometry to measure JCPyV attachment
SVG-A cells were cultured to 100% confluency in 6-well plates (Grenier Bio-One) and
were treated with a DMSO control or 2-APB (300 µM) in complete MEM at 37oC for 2
h. Cells were then removed from plates by washing with 1XPBS, then incubated with
Cellstripper (Corning). SVG-A cells were pelleted at 376 x g at 4oC for 5 min and
washed in 1XPBS. Cells were incubated with Alexa-488 fluorescently labeled JCPyV
(JCPyV-488) in PBS (100 µL total volume) on ice for 2 h, agitating every 15 min.
Following incubation, cells were washed and pelleted by centrifugation before being
resuspended in a final volume of 500 µL of 1XPBS. Viral attachment (JCPyV-488) was
examined utilizing a BD LSRII (BD Biosciences) with a 488 laser excitation line
(Benton, Dickinson, and Company). Data were analyzed based upon 10,000 events using
BD FACSDIVA (Benton, Dickinson, and Company) and FlowJo software (Tree Star,
Inc.).
16

Trypan blue quenching assay
SVG-A cells were plated to 100% confluency in 6-well plates (Grenier Bio-One) and
pretreated with complete MEM containing either DMSO control or 2-APB (300 µM) at
37oC for 2 h. Cells were then harvested by washing cells with 1XPBS, then incubated
with Cellstripper (Corning) at 37oC for 5 min. Cells were centrifuged at 375 x g at 4oC
for 5 min. The pellet was washed with 1XPBS, cells were pelleted again, and finally
resuspended in phenol-free complete MEM and chilled at 4oC for 30 min. Cells were
pelleted and resuspended with JCPyV-488 and incubated at 4oC for 1.5 h with agitation
every 15 min. Post incubation, cells were resuspended with cold phenol-free complete
MEM and were either fixed (attachment) or incubated at 37oC for 90 min (entry). At 0 or
90 min post-incubation, cells were pelleted and resuspended in 4% PFA on ice for 10
min. Cells were then washed and resuspended in 1XPBS or 1XPBS with Trypan blue
(0.016%) in a final volume of 500 µL. Addition of Trypan blue to pre-treated JCPyV-488
incubated cells quenches extracellular fluorescence. Therefore, only internalized JCPyV488 would remain detectable to the flow cytometer. Analysis for viral internalization was
completed utilizing a BD LSRII equipped with a 488 laser line. Data were analyzed with
BD FACSDIVA (Becton, Dickinson and Company) and FlowJo software (Tree Star,
Inc.). Quenched (addition of Trypan blue) and protected samples (without Trypan blue)
from DMSO- and 2-APB-treated cells were assessed by flow cytometry to determine
viral attachment (incubation at 4oC only) and viral internalization (incubation at 37oC).
Percent protected fluorescence of average FITC readings from quenched and protected
samples were calculated by normalizing the mean fluorescence to cells alone. Three
samples were examined for each condition, with each sample containing 10,000 events.
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ER-GCaMP assay
SVG-A cells were plated 5e3 cells/well in a 96-well black chimney, clear bottom plate
(Grenier Bio-One) and incubated O/N at 37oC in complete MEM. Cells were then
transfected with a plasmid containing the ER-GCaMP (provided by Drs. Tim Ryan and
Julie Gosse) with Fugene6 (Promega) at a 0.2µg of DNA to 0.6µL of Fugene6 in a
volume of 10 µL/well in phenol-free complete MEM. Cells were incubated at 37oC for 24
h. The transfection treatment was then removed and replaced with complete MEM and
incubated at 37oC for 48 h. Cells were then washed with a Tyrode’s buffer (pH 7.4) at
37oC for 30 min. Cells treated with ionomycin or Tyrode’s buffer immediately before
analysis every 45 sec for 1h (excitation 485/20 and emission 528/20) using a BioTek
Synergy2 plate reader with Gen5 (version 5.0). Other cells were infected with JCPyV in
Tyrode’s buffer at a MOI 0.5 FFU/cell and read every min for 3 h (excitation 485/20 and
emission 528/20) using a BioTek Synergy2 plate reader with Gen5 (version 5.0).
Readings were normalized to non-transfected or uninfected samples.
Statistical Analysis
Significance was determined utilizing the Microsoft Excel student’s paired t-test for at
least triplicate samples. P values of < 0.05 were considered statistically significant.
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RESULTS

JCPyV directly induces Ca2+ flux from the ER
Viral-host cell interactions that occur during viral attachment can induce Ca2+ flux
from the ER to drive viral processes such as internalization, trafficking, replication, and
egress by activating critical proteins31. The role of JCPyV-induced Ca2+ flux has
remained unclear, yet recent studies have shown that ERK26 and NFAT28, which can also
be regulated by IP3R-mediated Ca2+ release, are critical modulators of the JCPyV
infectious lifecycle. To
examine whether Ca2+
release occurs during
JCPyV infection, an assay
was developed to measure
Figure 5. ER-GCaMP is efficient for examining ER Ca2+ flux. SVG-A
cells were transfected with an ER-GCaMP plasmid and incubated for 48 h.
Cells were then treated with ionomycin. At selected time points, cells were
analyzed for fluorescence intensity with a BioTek plate reader at 37oC every
45 sec for 1 h to determine relative fluorescence units (RFUs). Data are
representative of three experiments completed with three samples per
treatment. ER-GCaMP is efficient for examining ER Ca2+ flux.

ER- specific Ca2+ release in
SVG-A cells, a glial cell
line optimized for studies of

JCPyV infection. SVG-A cells were transfected with a plasmid containing the sequence
for a molecular reporter of ER-specific Ca2+ signaling, ER-GCaMP. The molecule
consists of an enhanced green fluorescent protein (GFP) synthetically attached to a CaM
and M13 peptide, both of which act as Ca2+ binding domains, with an ER localization
signal34. ER-GCaMP can only be excited and emit a signal when bound to Ca2+ ions
within the ER. Emission is detected via plate reader and measured as relative

19

fluorescence units (RFUs). Therefore, changes in fluorescence measurements represent
the relative levels of Ca2+ within the ER.
To determine the sensitivity of the assay, transfected cells were examined for
RFUs over the course of 1 h after adding ionomycin, a Ca2+ ionophore, or a CTL
(DMSO) to the cells (Figure 5). Results showed a stable expression of RFUs in the CTLtreated cells for the duration of the experiment while those treated with ionomycin
showed a complete abolishment of relative fluorescence units immediately upon addition.
These results therefore
indicate that this assay is
sensitive enough to detect
variations in ER Ca2+
concentrations. Next, to
Figure 6. JCPyV induces Ca2+ release from ER. SVG-A cells were transfected
with an ER-GCaMP plasmid and incubated for 48 h. Cells were then infected with
JCPyV (MOI = 0.5 FFU/cell). At selected time points, cells were analyzed for
fluorescence intensity with a BioTek plate reader at 37oC every min for 3 h to
determine relative fluorescence units (RFUs). Data are representative of three
experiments completed with six samples per treatment. JCPyV infection induces
ER Ca2+ release.

determine the effect of
JCPyV infection on Ca2+
flux, cells were mock
infected (uninfected) or
infected. Fluorescence was
recorded for six samples
every min for 3 h. Mockinfected cells retained a
stable expression of RFUs

Figure 7. 2-APB is efficient for inhibiting ER Ca2+ flux. SVG-A cells were
transfected with an ER-GCaMP plasmid and incubated for 48 h. Cells were pretreated
for 2-APB or CTL (DSMO) then treated with ionomycin. At selected time points,
cells were analyzed for fluorescence intensity with a BioTek plate reader at 37oC
every 45 sec for 1 h to determine relative fluorescence units (RFUs). ER-GCaMP is
efficient for examining ER Ca2+ flux.
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throughout the duration of
the experiment, while the

infected cells showed a complete abolishment at the time of infection (Figure 6). These
results therefore suggest that JCPyV host-cell interactions are capable of eliciting an ER
Ca2+ during infection, presumably as early at the viral attachment and entry5,12,22.

Figure 8. Pretreatment of cells with 2-APB inhibits nuclear expression of TAg. A) HEK-5-HT2AR cells were treated for 1 h or
B) SVG-A cells were treated for 2 h with either a control (CTL) or 2-APB at 37oC and then infected with JCPyV at a MOI of 0.1
FFU/cell. Cells were fixed, stained, and quantified for TAg expression by indirect immunofluorescence microscopy. Data represent
the average percent infection for 3 visual fields for triplicate samples. Experiment was completed once in triplicate. Error bars
represent the SD. *, P<0.03 and **, P<0.005, and ***P<0.005. Treatment with 2-APB reduces JCPyV infection.

IP3R-mediated Ca2+ flux is required for JCPyV infection
While the ER-GCaMP studies revealed that JCPyV infection results in a release of ER
Ca2+ stores at times consistent with viral attachment and entry, the role of Ca2+ flux on
the JCPyV infectious cycle was unclear. Upon release from the ER, free Ca2+ ions act as
ubiquitous secondary regulators for cellular functions35. Other viruses including HIV,
influenza virus, and Dengue virus have been shown to induce Ca2+ flux from the ER to
drive various steps in their infectious processes31,32. Therefore, to examine the effect of
ER Ca2+ flux inhibition, cells were pretreated with various chemical inhibitors of the
IP3R-mediated Ca2+ release signaling cascade to examine their effect on JCPyV infection.
The competitive inhibitor of the IP3R, 2-APB36 (Figure 4), was tested for efficacy by
determining whether it could inhibit Ca2+ flux from the ER utilizing the ER-GCaMP
assay. Results showed that cells pretreated with 300 µM of 2-APB compared to CTL-
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treated cells retained higher relative fluorescence when treated with ionomycin (Figure
7). These results therefore suggest that 2-APB is efficient at inhibiting Ca2+ flux from the
ER.
To further characterize whether Ca2+ flux is required for JCPyV infection, the
kidney cell line HEK293A that stably express 5-HT2AR22 (HEK-5-HT2AR) and the glial
cell line SVG-A cells were pretreated with 2-APB at indicated concentrations for 2 h,
then infected with JCPyV. Infection was quantified using a fluorescence focus assay
(FFA) of viral infectivity. Treatment of SVG-A cells with 2-APB lead to a dosedependent decrease in nuclear expression of both the early gene product T Ag (Figure 8)
and late gene product VP1 (Figure 9). Additionally, SVG-A cells were pretreated with
Xestospongin C, another competitive inhibitor of the IP3R, and then examined by FFA
for VP1 expression (Figure 10).
These results indicated a
significant decrease of ~20% in
viral infection, thereby
corroborating with the 2-APB
results (Figure 10). Given that
PLC regulates the production of
IP3 (Figure 4), SVG-A cells were
pretreated with a PLC inhibitor

Figure 9. SVG-A cells treated with 2-APB inhibits nuclear expression
of VP1. SVG-A cells were treated with either a control (CTL) or 2-APB,
an inhibitor of ER Ca2+ release, then infected with JCPyV at an MOI of 0.1
FFU/cell at 37oC for 1 h. Cells were fixed, stained, and quantified for VP1
expression by indirect immunofluorescence microscopy. Data represent the
average % infection for 3 visual fields for triplicate samples. Data are
representative of three experiments completed in triplicate. Error bars
represent the SD. *, P<0.05 and **, P<0.005. Treatment with 2-APB
prevented JCPyV infection.

(U73122) or DMSO control for 24 h prior to infection. Infectivity was scored using a
FFA and cells were examined for VP1 expression. Cells treated with U73122
demonstrated a ~20% decrease in JCPyV infection in comparison to DMSO control-
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treated cells (Figure 11), suggesting the importance of the IP3R signaling pathway in
JCPyV infection. To ensure chemical treatments were not inducing cellular cytotoxicity,
SVG-A cells were subjected to treatments as described in the experimental procedures
and a cellular proliferation assay was performed (Figure 12). The concentrations used in
these studies did not exhibit cellular
toxicity. Together, these data suggest
that JCPyV utilizes IP3R-mediated
Ca2+ flux from host cell ER stores to
drive infection.
Figure 10. Pretreatment of cells Xestospongin C inhibits nuclear
expression of VP1. SVG-A cells were pretreated with either a control
(CTL) or Xestospongin C (Xesto C) for 1 h, then infected with JCPyV
at an MOI of 0.1 FFU/cell at 37oC for 1 h. Media was added, and cells
incubated for 72 h. Post incubation, cells were fixed, stained, and
quantified for nuclear VP1 expression indirect immunofluorescence
microscopy. The bars represent the average number of infected cells
for 3 fields of view for triplicate samples. The error bars represent the
SD. Xestospongin C resulted in ~30% decrease in JCPyV infection *,
P<0.04.

JCPyV attachment is independent of
IP3R-mediated Ca2+ flux
Analysis of Ca2+ release from the ER
upon JCPyV infection using the ERGCaMP assay revealed that Ca2+
release occurs immediately following
infection (0-3 h), and which is a time
consistent with viral attachment and
entry5,12,20,22. To define whether
JCPyV depends on IP3R-mediated

Figure 11. Pretreatment of cells with U73122 inhibits nuclear
expression of VP1. SVG-A cells were pretreated with either a
control (CTL) or U73122 at 37ᴼC for 24 h, then infected for 1 h.
Media was added and cells incubated for 72 h. Post incubation, cells
were fixed, stained, and quantified for nuclear VP1 expression
indirect immunofluorescence microscopy. The bars represent the
average number of infected cells for 3 fields of view for triplicate
samples. Experiment was completed three times in triplicate. The
error bars represent the SD. U73122 resulted in a dose dependent
decrease in JCPyV infection. *, P<0.005.
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Ca2+ release from the ER Ca2+ flux,
viral attachment to cells treated with 2APB was measured by flow cytometry.
SVG-A cells were pretreated with 300

µM of 2-APB, or CTL (DMSO) at 37oC for 2 h. Cells were detached from plates,
suspended, and incubated at 4oC on ice to induce rigidity in the cell membranes to limit
JCPyV internalization. Treated cells were then incubated with an Alexa-488-labeled
JCPyV (JCPyV-488) at 4oC on ice to mediate viral attachment for 90 min37. Viral
attachment was measured by flow cytometry analysis of the mean fluorescence (JCPyV488) of 10,000 events per treatment (Figure 13). Results showed no significant change in
the mean fluorescence between the 2-APB- or control-treated cells, and that fluorescence
is correlated to the presence of JCPyV-488 attachment to SVG-As. These results suggest
that inhibition of Ca2+ release from the ER with 2-APB treatment does not affect JCPyV
binding to host cells. Therefore, it is likely that Ca2+ flux regulates a post-attachment step
in the JCPyV lifecycle.

Figure 12. Chemical inhibitors do not affect cellular proliferation. SVGA cells were treated with either a control (CTL)
A) 2-APB for 2 h, B) U73122 for 24 h, or C) Xestospongin C for 1h at 37ᴼC. Post incubation, treatment was removed and
replaced with an equivalent volume of media, and cells were incubated at 37ᴼC for a total of 72 h. MTS was then added to
each well and incubated for 1h at 37ᴼC. Absorbance was measured at 490 nm. Data represent the average absorbance for
triplicate samples. Data are representative of three experiments completed in triplicate. Error bars represent SD. Pretreating
SVGA cells with 2-APB, U73122, or Xestospongin C does not induce cytotoxicity.
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JCPyV internalization is independent of IP3R-mediated Ca2+ flux
Recent data has demonstrated the importance of ER Ca2+ signaling in driving viral
internalization in the infectious viral lifecycles, including the viral entry step the herpes
simplex virus38. Further, ER Ca2+ flux occurs very early during JCPyV infection (Figure
6), suggesting that Ca2+ flux may regulate viral internalization. To determine whether
Ca2+ flux regulated JCPyV entry, SVG-A cells were pretreated with 300 µM of 2-APB or
a CTL (DMSO), and cells were
suspended in 1XPBS and incubated at
4oC on ice for 30 mins to induce
membrane rigidity. Cells were then
incubated with JCPyV-488 in 1XPBS at
either at 4oC on ice (attachment) and
fixed or shifted to 37oC (entry) for 90 min
(Figure 14). Post incubation, cells were
washed and treated with or without
Figure 13. 2-APB does not affect JCPyV attachment to
SVG-A cells. To examine viral binding, SVG-A cells were
pretreated for 2 h with 2-APB, DMSO (CTL), or PBS (Cells
alone) then incubated with fluorescently-labeled JCPyV
(JCPyV-488) on ice for 1 h. Cells were analyzed using flow
cytometry to detect JCPyV-488. The mean fluorescence
intensity was determined for 10,000 events measured.
Pretreatment of cells with 2-APB does not impact JCPyV
attachment.

Trypan blue, which quenches the
extracellular Alexa-488 fluorescence
while internalized fluorescent molecules
are protected from quenching37.

Triplicate samples were analyzed by flow cytometry (10,000 events for each sample).
Data was analyzed to determine the amount of virus that had been internalized (%
protected fluorescence), which revealed no change in mean fluorescence between the
control- or 2-APB- pretreated SVG-A cells (Figure 14). These results suggest that IP3R-
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mediated Ca2+ flux has no effect on JCPyV internalization. Therefore, it is hypothesized
that Ca2+ flux, which is required for JCPyV infection, affects a post-attachment and postinternalization step in the JCPyV replication cycle.
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DISCUSSION

Due the diverse role of Ca2+ in cellular signaling, it is defined as a ubiquitous
secondary signaling regulator in healthy cells and during times of human disease35.
Research has shown that specific viral-host cell interactions can elicit Ca2+ release from
the ER to promote viral infection27,31,36,38. Interestingly, Ca2+ flux can be initiated upon
ligand binding and activation of G-protein coupled receptors (GPCRs), which include the
5-HT2Rs that are required for JCPyV entry and infection22,23. Subsequent signaling
cascades are initiated and result in the activation of the IP3R, a Ca2+ ion channel located
within the membrane of the ER39. This free cytosolic Ca2+ is responsible for activating
various host transcription factors, proteins involved with endocytosis in addition to
dictating cellular proliferation and death, and membrane budding40.
This research has shown that JCPyV infection results in the release of ER Ca2+ at
times consistent with viral attachment and entry through a novel application of the ERGCaMP assay (Figure 6)20,34. Additionally, examination of both early and late viral gene
products revealed a dose-dependent decrease in viral protein expression in cells
pretreated with either an IP3R or PLC inhibitor. These results suggest that the Ca2+ flux
regulates a step in the JCPyV infectious cycle prior to transcription (Figure 8-10).
However, there was no change in either viral attachment or entry in the presence of the 2APB inhibitor (Figures 13 and 14), suggesting that Ca2+ flux has no effect on JCPyV
attachment or entry. Therefore, JCPyV-induced Ca2+ flux is hypothesized to regulate a
process post viral entry and prior to transcription and has the potential to regulate
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multiple steps in the JCPyV infectious cycle, such as trafficking, partial uncoating of the
viral capsid, and activation of host transcription factors.
Following internalization, JCPyV is trafficked through the cytoplasm within the
endocytic compartment via early endosomes and caveolin-1+ vesicles25,41. Early
endosome formation and function are
closely regulated by Ras-associated
binding protein 5 (Rab5)42. Rab5 is
activated via GTPases that are
regulated by GPCRs43. Rab5 recruits
Rab effector proteins, which are
responsible for endosomal fusion and
Figure 14. 2-APB does not affect JCPyV entry in SVG-A cells.
SVG-A cells were pretreated with 2-APB at 37oC for 2 h then
incubated with fluorescently-labeled JCPyV on ice for 1 h for viral
attachment. Cells were treated with or without trypan blue to
quench extracellular fluorescence or incubated at 37oC for 90 min
to mediate viral entry and subsequently treated with trypan blue.
Internalized virions were protected within the cell and capable of
detection using flow cytometry. Pretreatment of cells with 2-APB
does not affect JCPyV internalization.

trafficking42. As JCPyV has been
shown to require a specific family of
GPCRs, 5-HT2Rs, it is possible that
their activation not only mediates

viral internalization, but also induces ER Ca2+ flux to activate Rab5 for early endosomal
trafficking. Early endosomal trafficking is a necessary step in the JCPyV lifecycle, which
results in delivery of the virus to the ER where the capsid undergoes a partial uncoating4.
This uncoating process is required for viral deposition into the cytosol and eventual
translocation to the nucleus where the viral genome is released for transcription and viral
replication4. It is therefore possible that modulation of the ER Ca2+ release inhibits viral
trafficking and therefore reduces viral transcription. This would therefore be consistent
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with results showing inhibition of Ca2+ flux results in decreased expression of both early
and late viral gene products (Figure 8 and 9).
Additionally, it is also possible that IP3R-mediated ER Ca2+ flux, thereby altering
the ER’s internal environment, is affecting JCPyV capsid uncoating. Research has shown
that inhibiting the release of cellular Ca2+ stores negatively affects the viral uncoating
processes within the ER37. Research by Nelson et al. suggests that release of ER Ca2+
activates ER-localized enzymes responsible for mediating JCPyV uncoating37. Therefore,
it is possible that JCPyV induces IP3R-mediated ER Ca2+ to regulate the ERAD pathway
and subsequent capsid uncoating within the ER. This Ca2+ release would occur early in
the JCPyV lifecycle, which is demonstrated through the ER-GCaMP assay examining ER
Ca2+ in JCPyV infected cells (Figure 6). Failure of JCPyV to partially uncoat in the ER
would inhibit the delivery of the viral genome into the nucleus, and therefore inhibit viral
transcription. This is also consistent with the reduced expression of both early and late
viral gene products when IP3R-mediated Ca2+ release was inhibited with 2-APB (Figure
7).
Furthermore, ER Ca2+ flux could affect the activation of the protein kinase C
(PKC) signaling pathway, which occurs post-entry and prior to viral transcription in the
JCPyV lifecycle26. Cytosolic Ca2+ is capable of activating PKC, a kinase, which regulates
the MAPK signaling pathway44. PKC initiates the MAPK cascade by phosphorylating
Ras, which leads to the subsequent activation of Raf, MEK, and ERK44. Interestingly, the
ER-GCaMP results revealed that Ca2+ flux occurs immediately upon viral infection.
These results interestingly coincide with recent studies showing that the activation of
ERK through phosphorylation occurs shortly after JCPyV infection26. Interestingly, the
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activation of ERK has also been linked to the regulation of NFAT, a molecule known to
be a critical regulator in JCPyV transcription and infection28,45. Therefore, it is possible
that JCPyV induced Ca2+ release is promoting viral gene transcription by regulating
necessary transcription factors through the activation of PKC.
As Ca2+ is defined as a universal secondary regulator, the ion itself would not be a
viable target for either JCPyV infection or PML35. Inhibition of the ion could result in
host cell death and thus lead to serious medical complications. One example is the
importance of Ca2+ release in neuron activity. In this pathway glutamate activates a
GPCR to create IP3, which then binds to its receptor and induces a Ca2+ flux. This
calcium flux results in Ca2+-initiated Ca2+ release (CICR) and creates action potential
within the pacemaker neurons of a human brain29. Similarly, Ca2+ signaling is also a
critical regulator for muscle contraction, including muscles involved in regulating the
heart29. Thus, it would be better to utilize our understanding of the role Ca2+ signaling
pathway in regulating JCPyV infection to identify novel targets for JCPyV therapies. As
the data has shown that ER Ca2+ release fails to inhibit viral attachment or internalization,
yet it does have an effect on viral replication, and future research could help identify
possible therapeutic targets such as transcription factors (NFAT) or activation of kinases
such as ERK that regulate phosphorylation of transcription factors. Currently, there are
inhibitors for the phosphatase calcineurin (Cyclosporin A) which regulates NFAT, and
U0126 which inhibits ERK activation26,28. These could serve as the basis for developing
novel therapies.
Additionally, this research has described a new molecular assay sensitive enough
to detect changes in Ca2+ concentrations within a selected organelle during viral
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infection. This assay, along with the Ca2+ inhibition assays, has provided deeper insight
how viral-host cell interactions regulate JCPyV infection and specifically how IP3Rmediated Ca2+ release regulates viral infection and pathogenesis. These findings can be
applied broadly to the field of virology to increase our understanding of viral-induced
signaling pathways that drive viral infection, influence viral pathogenesis, and ultimately
influence human disease development.
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